CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 76 enrolled
Drug / intervention
Cohort 1:Nilotinib Oral Capsules (150mg or 300mg) +2 moredrug
Likely dose
Cohort 1:Nilotinib Oral Capsules (150mg or 300mg)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03205488
NCT03205488Phase 2Completed
CompareCT.gov

A Randomized, Double-Blind, Placebo-Controlled, Phase IIa, Parallel Group, Two Cohort Study to Define the Safety, Tolerability, Clinical and Exploratory Biological Activity of the Chronic Administration of Nilotinib in Participants With Parkinson's Disease

Northwestern University·interventional·Posted Jul 2, 2017·Updated Jul 22, 2020

In Brief

A Phase 2 clinical trial evaluating Cohort 1:Nilotinib Oral Capsules (150mg or 300mg), Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1), and 1 other intervention for Parkinson Disease. Completed, enrolled 76 participants across 24 sites.

Detailed Summary

This study will assess the safety and tolerability of daily oral administration of nilotinib (150-300mg once daily) in Parkinson's Disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease
CountriesUnited States
CollaboratorsUniversity of Rochester, University of Iowa, Michael J. Fox Foundation for Parkinson's Research

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJul 2, 2017
Enrollment StartOct 16, 2017
Primary CompletionAug 26, 2019
Study CompletionSep 28, 2019
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 9 years ago

Interventions

Cohort 1:Nilotinib Oral Capsules (150mg or 300mg)drug

2 capsules taken once daily

Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1)drug

2 capsules taken once daily

Placebodrug

2 capsules taken once daily